The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity:A Meta-Analysis  

作　　者：Mengqing Zhang Chu Lin Xiaoling Cai Ruoyang Jiao Shuzhen Bai Zonglin Li Suiyuan Hu Fang Lyu Wenjia Yang Linong Ji 

机构地区：[1]Department of Endocrinology and Metabolism,Peking University People’s Hospital,Beijing 100044,China

出　　处：《Biomedical and Environmental Sciences》2024年第6期607-616,共10页生物医学与环境科学（英文版）

基　　金：supported by The Beijing Natural Science Foundation[No.7202216];the National Natural Science Foundation of China[No.81970698 and No.81970708].

摘　　要：Objective Recent studies have indicated potential anti-inflammatory effects of glucagon-like peptide-1 receptor agonists(GLP-1RAs)on asthma,which is often comorbid with type 2 diabetes mellitus(T2DM)and obesity.Therefore,we conducted a meta-analysis to assess the association between the administration of glucagon-like peptide-1(GLP-1)receptor-based agonists and the incidence of asthma in patients with T2DM and/or obesity.Methods PubMed,Web of Science,Embase,the Cochrane Central Register of Controlled Trials,and Clinicaltrial.gov were systematically searched from inception to July 2023.Randomized controlled trials(RCTs)of GLP-1 receptor-based agonists(GLP-1RA,GLP-1 based dual and triple receptor agonist)with reports of asthma events were included.Outcomes were computed as risk ratios(RR)using a fixedeffects model.Results Overall,39 RCTs with a total of 85,755 participants were included.Compared to non-GLP-1 receptor-based agonist users,a trend of reduced risk of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments,although the difference was not statistically significant[RR=0.91,95%confidence interval(CI):0.68 to 1.24].Further Subgroup analyses indicated that the use of light-molecular-weight GLP-1RAs might be associated with a reduced the risk of asthma when compared with non-users(RR=0.65,95%CI:0.43 to 0.99,P=0.043).We also performed sensitivity analyses for participant characteristics,study design,drug structure,duration of action,and drug subtypes.However,no significant associations were observed.Conclusion Compared with non-users,a modest reduction in the incidence of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments.Further investigations are warranted to assess the association between GLP-1 receptor-based agonists and the risk of asthma.

关 键 词：Glucagon-like peptide-1 receptor agonists Twincretins ASTHMA Type 2 diabetes mellitus OBESITY 

分 类 号：R587.1[医药卫生—内分泌] R589.2[医药卫生—内科学] R562.25[医药卫生—临床医学]